Skip to main content
TipRanks
Go Ultimate75% OFF

GenSight Biologics SA (0RIM) Share Price & Analysis

2 Followers

0RIM Stock Chart & Stats

€0.08-€0.00(-1.32%)
At close: 4:30 PM GMT
€0.075€0.1€0.125Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
EUR 0.08 - EUR 0.08
52-Week Range
EUR 0.06 - EUR 0.15
Previous Close
EUR 0.08
Volume
N/A
Average Volume (3M)
25.00K
Market Cap
EUR 18.71M
Enterprise Value
EUR 29.15M
Total Cash (Recent Filing)
EUR 1.67M
Total Debt (Recent Filing)
EUR 12.84M
Price to Earnings (P/E)
―
Beta
0.50
Next Earnings
Mar 19, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Focused Therapeutic Pipeline

The company is concentrated on specialized gene-therapy and optogenetics approaches for severe retinal disorders, giving its development strategy a clear therapeutic focus. If clinical and regulatory progress continues, these programs could create meaningful value through differentiated treatments rather than broad, unfocused research activity.

Lower Debt Burden

Debt reduction is a constructive balance-sheet development because it can lower financing pressure and improve flexibility relative to the company’s prior position. Although solvency remains constrained, reducing borrowings may help preserve resources for advancing the pipeline and managing near-term obligations.

Improved Cash-burn Trend

The smaller operating cash outflow indicates some improvement in cash discipline or spending intensity compared with the prior year. Sustaining and extending this trend would lengthen available funding capacity and reduce the pace at which external capital is needed to support ongoing development.

Bears Say

Severe Revenue Collapse

The near-total revenue collapse demonstrates that the business currently has very limited commercial scale and weak revenue visibility. Without a durable recovery, the company will have less internally generated funding for research and development, leaving future progress heavily dependent on financing or successful product advancement.

Persistent Unprofitability

Recurring operating and net losses show that the company remains far from breakeven and has not yet converted its development activities into sustainable earnings. Continued losses can consume capital, restrict strategic flexibility, and increase the financial burden of bringing its therapies toward commercialization.

Negative Shareholders’ Equity

Persistent negative equity is a significant solvency weakness because liabilities exceed the recorded asset base and the capital structure has limited financial resilience. This condition can increase reliance on external funding, constrain investment choices, and make the company more vulnerable if capital markets become less accessible.

GenSight Biologics SA News

0RIM FAQ

What was GenSight Biologics SA’s price range in the past 12 months?
GenSight Biologics SA lowest share price was €0.06 and its highest was €0.15 in the past 12 months.
What is GenSight Biologics SA’s market cap?
GenSight Biologics SA’s market cap is €18.71M.
When is GenSight Biologics SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GenSight Biologics SA’s earnings last quarter?
GenSight Biologics SA released its earnings results on Sep 29, 2026. The company reported -€0.05 earnings per share for the quarter.
Is GenSight Biologics SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does GenSight Biologics SA pay dividends?
GenSight Biologics SA does not currently pay dividends.
What is GenSight Biologics SA’s EPS estimate?
GenSight Biologics SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GenSight Biologics SA have?
GenSight Biologics SA has 246,217,330 shares outstanding.
What happened to GenSight Biologics SA’s price movement after its last earnings report?
GenSight Biologics SA reported an EPS of -€0.05 in its last earnings report. Following the earnings report the stock price went down -12.281%.
Which hedge fund is a major shareholder of GenSight Biologics SA?
Currently, no hedge funds are holding shares in GB:0RIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology